Abeona Therapeutics (ABEO)
(Delayed Data from NSDQ)
$4.98 USD
-0.12 (-2.35%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $4.98 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ABEO 4.98 -0.12(-2.35%)
Will ABEO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ABEO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABEO
Philips (PHG) Showcases New AI-Based Solutions at the RSNA
Philips (PHG) to Showcase New Innovations & Cardiac Solutions
ABEO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Philips (PHG) Expands Partnership to Build Angio CT Solution
Philips (PHG) Alerts Users of Health Hazards of Therapy Masks
Ultragenyx's (RARE) Q2 Earnings Miss Estimates, Revenues Up
Other News for ABEO
Insider Sale: Director Mark Alvino Sells Shares of Abeona Therapeutics Inc (ABEO)
Insider Sale: Director Christine Silverstein Sells Shares of Abeona Therapeutics Inc (ABEO)
Stifel Nicolaus Sticks to Their Buy Rating for Abeona Therapeutics (ABEO)
Abeona Therapeutics files for $300M securities offering
Abeona Therapeutics files $300M mixed securities shelf